Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in chronic kidney disease
2022-002721-99Phase 2Terminated
- Sponsor
- Klinikum Nürnberg
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of balcinrenone in chronic kidney disease (CKD), sponsored by Klinikum Nürnberg. Primary endpoints: Change from baseline in 24-hour urine glucose excretion at day 3 and Change from baseline in 24-hour urine glucose excretion at day 28. Started Jan 2023; status: terminated.
02
Drugs
balcinrenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-002721-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002721-99.